SecBot SecBot

FBRX

Forte Biosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001419041 Biotech & Drug Discovery
No price
Market cap
$1.6B
Small cap
Median target
$77.00
range $61.00–77.00
Short interest
1.63M
≈7.7% of shares · −14.3%
Days to cover
1.5
at average volume
Insider net
$0
no open-market trades · since Aug 27
New fund stakes
0
Q3 2026 13F · 10 exits
Filing reports
15
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 6 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 6/6

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Aug 27. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 0 added (0 new), 10 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.005 → −$1.090 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −14.3% to 1.63M shares. 1.5 days to cover, ≈7.7% of shares.

Who's buying

13F· Q3 2026
0
new positions
10
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCEXIT0$0.00
FMR LLCEXIT0$0.00
FEDERATED HERMES, INC.EXIT0$0.00
VANGUARD CAPITAL MANAGEMENT LLCEXIT0$0.00
BlackRock, Inc.EXIT0$0.00
BlackRock, Inc.DOUBLED1,222,862$26.0M
VANGUARD CAPITAL MANAGEMENT LLCADD861,737$18.3M
Woodline Partners LPDOUBLED712,753$15.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jul 2026
Recent actions
DateFirmActionRating
Jul 28, 2026Barclays
DOWNGRADE
DOWNGRADEEqual-Weight
Jul 21, 2026Barclays
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$0
open-market buys or sells · since Aug 27
DateInsiderTypeValue
Aug 27, 2026
GRYSKA DAVID W
Director
Aug 27, 2026
TO ISSUER2,000 sh
Aug 27, 2026
GRYSKA DAVID W
Director
Aug 27, 2026
TO ISSUER18,353 sh
Aug 27, 2026
VINCENT RICHARD G
Director
Aug 27, 2026
TO ISSUER18,353 sh
Aug 27, 2026
GRYSKA DAVID W
Director
Aug 27, 2026
TENDER5,940 sh
Aug 27, 2026
FINCK BARBARA K
Director
Aug 27, 2026
TO ISSUER1,000 sh
Aug 27, 2026
GRYSKA DAVID W
Director
Aug 27, 2026
TO ISSUER2,000 sh
Aug 27, 2026
Riley Antony A
CHIEF FINANCIAL OFFICER
Aug 27, 2026
TO ISSUER750 sh
Aug 27, 2026
FINCK BARBARA K
Director
Aug 27, 2026
TO ISSUER166 sh

Earnings setup

Estimates
−$1.09
EPS estimate, this quarter
−8%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.09-$1.09–-$1.09-16.9%$0.00
Next Q-$1.11-$1.11–-$1.11-13.4%$0.00
Current FY-$4.48-$4.48–-$4.48-16.8%$0.00
Next FY-$4.08-$5.91–-$2.89-0.9%$0.00

Short side

FINRA· Aug 14, 2026
1,632,328
shares short
-14.3%
vs prior settlement
1.5
days to cover
≈7.7%
of shares outstanding
Trading halts
Aug 26, 2026DeletionResumed
Jul 9, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Affinity Asset Advisors, LLC filed an amendment to Schedule 13G reporting a complete exit from Forte Biosciences…
SC 13G/A · Impact 5/10
Nov 13, 2026 SEC
MPM BioImpact LLC filed an amendment to Schedule 13G reporting a complete exit from Forte Biosciences, reducing its…
SC 13G/A · Impact 5/10
Nov 12, 2026 Earnings calendar
FBRX Q3 2026 Earnings Scheduled · 2026-11-12
Nov 4, 2026 SEC
Tybourne Capital Management (HK) Ltd and related entities filed an amendment to Schedule 13G reporting a reduction of…
SC 13G/A · Impact 4/10
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
FMR LLC · EXIT
0 shares ($0.00)
Aug 27, 2026 Insider
GRYSKA DAVID W disposed of 2,000 shares
Director
Aug 27, 2026 Insider
GRYSKA DAVID W disposed of 18,353 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

15 filings · 1 bullish · 11 bearish · 1 mixed · 2 neutral
All FBRX filing & press-release reports (15)